Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02974725 | A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma | terminated | Phase 1 | 241 | Novartis PharmaceuticalsINDUSTRY | 11 | Apr 13, 2025 | clinicaltrials |
| NCT04625205 | A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma | terminated | Phase 1 | 22 | BioNTech US Inc.INDUSTRY | 2 | Apr 6, 2025 | clinicaltrials |
| NCT03829501 |
| terminated |
| Phase 1 / Phase 2 |
| 222 |
| Kymab LimitedINDUSTRY |
| 6 |
| Apr 2, 2025 |
| clinicaltrials |
| NCT05695898 | XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy | terminated | Phase 1 | 6 | University of California, San FranciscoOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT04990479 | Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma | terminated | Phase 1 | 7 | Nouscom SRLINDUSTRY | 3 | Mar 20, 2025 | clinicaltrials |
| NCT05576077 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors(STARLING) | terminated | Phase 1 | 31 | Turnstone Biologics, Corp.INDUSTRY | 2 | Mar 10, 2025 | clinicaltrials |
| NCT03997474 | ATL001 in Patients With Metastatic or Recurrent Melanoma | terminated | Phase 1 / Phase 2 | 13 | Achilles Therapeutics UK LimitedINDUSTRY | 2 | Mar 7, 2025 | clinicaltrials |
| NCT05909995 | Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors | terminated | Phase 1 | 8 | Incyte CorporationINDUSTRY | 3 | Feb 18, 2025 | clinicaltrials |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | terminated | Phase 1 | 133 | Seagen Inc.INDUSTRY | 6 | Feb 10, 2025 | clinicaltrials |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | terminated | Phase 1 / Phase 2 | 15 | Aminex Therapeutics, Inc.INDUSTRY | 2 | Dec 24, 2024 | clinicaltrials |
| NCT04967196 | Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma | terminated | Phase 1 | 6 | Mayo ClinicOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT03950635 | Dietary Intervention in Patients with a History of Melanoma | terminated | Phase 1 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT01217411 | RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06448364 | A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination(LTbR) | terminated | Phase 1 | 4 | PfizerINDUSTRY | 2 | Nov 6, 2024 | clinicaltrials |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | terminated | Phase 1 | 15 | Molecular Templates, Inc.INDUSTRY | 1 | Nov 1, 2024 | clinicaltrials |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer(PDL1x41BB) | terminated | Phase 1 | 160 | Inhibrx Biosciences, IncINDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT02097225 | Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | terminated | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Oct 16, 2024 | clinicaltrials |
| NCT03712358 | PVSRIPO for Patients With Unresectable Melanoma | terminated | Phase 1 | 12 | Istari Oncology, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03978611 | A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment | terminated | Phase 1 | 11 | Bristol-Myers SquibbINDUSTRY | 6 | Jul 24, 2024 | clinicaltrials |
| NCT04198818 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors | terminated | Phase 1 / Phase 2 | 37 | Haihe Biopharma Co., Ltd.INDUSTRY | 2 | Jul 19, 2024 | clinicaltrials |
| NCT03685591 | PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 49 | PfizerINDUSTRY | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | terminated | Phase 1 | 78 | ADC Therapeutics S.A.INDUSTRY | 3 | Jun 13, 2024 | clinicaltrials |
| NCT04655157 | Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma(QUAD01) | terminated | Phase 1 / Phase 2 | 2 | Jason J. Luke, MDOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT00199342 | A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma | terminated | Phase 1 / Phase 2 | 5 | Kyowa Kirin, Inc.INDUSTRY | 1 | May 3, 2024 | clinicaltrials |
| NCT04879017 | FHD-286 in Subjects With Metastatic Uveal Melanoma | terminated | Phase 1 | 76 | Foghorn Therapeutics Inc.INDUSTRY | 3 | Apr 25, 2024 | clinicaltrials |
| NCT05709821 | IMM60 and Pembrolizumab in Melanoma and NSCLC | terminated | Phase 1 / Phase 2 | 1 | iOx TherapeuticsINDUSTRY | 3 | Apr 24, 2024 | clinicaltrials |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | terminated | Phase 1 | 13 | PfizerINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT03727789 | CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma | terminated | Phase 1 | 7 | Roswell Park Cancer InstituteOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT02723006 | Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma | terminated | Phase 1 | 22 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 5, 2024 | clinicaltrials |
| NCT00003552 | Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma | terminated | Phase 1 / Phase 2 | — | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT04455503 | Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 | terminated | Phase 1 / Phase 2 | 15 | Evaxion Biotech A/SINDUSTRY | 1 | Feb 21, 2024 | clinicaltrials |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | terminated | Phase 1 | 3 | Stanford UniversityOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | terminated | Phase 1 | 87 | Atreca, Inc.INDUSTRY | 1 | Dec 29, 2023 | clinicaltrials |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | terminated | Phase 1 | 10 | University of FloridaOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT04589832 | Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma | terminated | Phase 1 / Phase 2 | 6 | Arkadiusz Z. Dudek, MDOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT02425306 | Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma(Mel63; CHAMP) | terminated | Phase 1 / Phase 2 | 48 | Craig L Slingluff, JrOTHER | 1 | Oct 30, 2023 | clinicaltrials |
| NCT02743611 | Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma | terminated | Phase 1 / Phase 2 | 4 | Bellicum PharmaceuticalsINDUSTRY | 1 | Oct 5, 2023 | clinicaltrials |
| NCT03272464 | INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors. | terminated | Phase 1 | 1 | Massachusetts General HospitalOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT01559818 | A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001 | terminated | Phase 1 / Phase 2 | 10 | Immodulon Therapeutics LtdINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03399448 | NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) | terminated | Phase 1 | 3 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03637803 | Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors | terminated | Phase 1 / Phase 2 | 63 | 4D pharma plcINDUSTRY | 1 | Jun 1, 2023 | clinicaltrials |
| NCT02961283 | Study of ASN003 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 24 | Asana BioSciencesINDUSTRY | 1 | May 9, 2023 | clinicaltrials |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | terminated | Phase 1 | 159 | Seagen Inc.INDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT04834973 | A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma | terminated | Phase 1 / Phase 2 | 3 | QBiotics Group LimitedINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT02890368 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides | terminated | Phase 1 | 56 | PfizerINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT03878719 | Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma | terminated | Phase 1 | 1 | PfizerINDUSTRY | 1 | Apr 3, 2023 | clinicaltrials |
| NCT00667953 | Study of Temzolomide and Gleevec in Advanced Melanoma | terminated | Phase 1 / Phase 2 | 32 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT04042480 | A Study of SGN-CD228A in Advanced Solid Tumors | terminated | Phase 1 | 88 | Seagen Inc.INDUSTRY | 5 | Mar 23, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Apr 13, 2025source: clinicaltrials